Current Hepatitis Reports

, Volume 12, Issue 3, pp 143–148

The Evolution of HCV Treatment in Taiwan

Authors

  • Chung-Feng Huang
    • Institute of Clinical Medicine, College of MedicineKaohsiung Medical University
    • Hepatobiliary Division, Department of Internal Medicine and Hepatitis CenterKaohsiung Medical University Hospital
    • Department of Occupational Medicine, Kaohsiung Municipal Ta-Tung HospitalKaohsiung Medical University Hospital, Kaohsiung Medical University
  • Wan-Long Chuang
    • Hepatobiliary Division, Department of Internal Medicine and Hepatitis CenterKaohsiung Medical University Hospital
    • Faculty of Internal Medicine, School of Medicine, College of MedicineKaohsiung Medical University
    • Hepatobiliary Division, Department of Internal Medicine and Hepatitis CenterKaohsiung Medical University Hospital
    • Faculty of Internal Medicine, School of Medicine, College of MedicineKaohsiung Medical University
Global Perspectives: Taiwan and Asia (ML Yu and RN Chien, Section Editors)

DOI: 10.1007/s11901-013-0172-8

Cite this article as:
Huang, C., Chuang, W. & Yu, M. Curr Hepatitis Rep (2013) 12: 143. doi:10.1007/s11901-013-0172-8

Abstract

The treatment strategies used in Taiwan for patients with chronic hepatitis C (CHC) have evolved from conventional interferon monotherapy, consensus interferon therapy, conventional interferon/ribavirinand to pegylated interferon/ribavirin combination therapy. In the past two decades, the sustained virological response (SVR) rate in Taiwanese patients improved from 6 to 75-90 %. By following genotype-guided therapy, an SVR rate of 75-80 % and 85-95 % could be achieved in Taiwanese patients with HCV-1 and HCV-2 infections, respectively. The study of HCV viral kinetics has facilitated studies in Taiwan regarding response-guided therapy with tailored regimens. The majority of Taiwanese patients can be treated successfully with pegylated interferon/ribavirin. The application of IL-28B genetic tests and the insight provided by the viral kinetics might aid in selecting the best candidates for treatment with direct antivirals in the near future in Taiwan.

Keywords

HCV Treatment Taiwan

Copyright information

© Springer Science+Business Media New York 2013